Champions Oncology to Present Eight Studies on Predicting Cancer Drug Response at AACR 2026
核心洞察
Champions Oncology will present eight poster presentations at the 2026 AACR Annual Meeting demonstrating how clinically relevant models can reduce translational risk in oncology drug development.
The research spans key cancer areas including KRAS (搜索)-mutant tumors, ovarian cancer (搜索), glioblastoma (搜索), radiopharmaceuticals (搜索), antibody-drug conjugates (搜索), and CAR-T therapies (搜索).
The studies utilize patient-derived models combined with integrated molecular, functional, and phenotypic data to improve therapeutic response prediction and identify actionable biomarkers.
Champions Oncology, Inc. (Nasdaq:CSBR) announced it will present new data across eight poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17-22, 2026, in San Diego, California. The global leader in clinically relevant oncology research models and translational solutions will showcase research demonstrating how clinically relevant models and integrated data can reduce translational risk and guide development decisions.
Comprehensive Research Portfolio Across Key Cancer Areas
The presentations will highlight research across key areas of oncology drug development, including KRAS (搜索)-mutant tumors, ovarian cancer (搜索), glioblastoma (搜索), radiopharmaceuticals (搜索), antibody-drug conjugates (搜索) (ADCs), and CAR-T therapies (搜索). Together, the data underscore Champions Oncology's focus on helping biopharma partners better understand therapeutic response and resistance, identify actionable biomarkers, and make more informed development decisions earlier in the pipeline.
Using clinically relevant, patient-derived models together with integrated molecular, functional, and phenotypic data, the studies demonstrate how translationally relevant preclinical approaches can improve prediction, reduce development risk, and strengthen the connection between tumor biology and clinical strategy.
Addressing Critical Challenges in Oncology R&D
"At AACR 2026, we are presenting data that directly address one of the biggest challenges in oncology R&D, making better decisions earlier," said Rob Brainin, Chief Executive Officer of Champions Oncology. "By combining clinically relevant models with deep molecular and functional data, we can help our partners understand response, anticipate resistance, and move forward with greater confidence."
The eight studies demonstrate how translationally relevant preclinical approaches can improve prediction capabilities and reduce development risk by strengthening the connection between tumor biology and clinical strategy. This approach aims to help pharmaceutical partners better understand therapeutic response patterns and resistance mechanisms across diverse cancer types.
Conference Engagement and Collaboration Opportunities
Champions Oncology scientists will be available throughout AACR 2026 to discuss study design, analytical approaches, and collaboration opportunities. The company's presence at the conference reflects its commitment to advancing oncology drug development through improved predictive modeling and translational research approaches.